Studies have shown that inhibiting MRPL13 can slow down the proliferation of breast cancer cells and EMT process, while reducing the resistance of non-small cell lung cancer cells to anthracyclines chemotherapy drugs. The gene discussed is MRPL13; the disease is breast cancer.